Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C

Xin Gao Pharmerit North America LLC, Bethesda, MD, USA. [email protected]

Jennifer M Stephens Pharmerit North America LLC, Bethesda, MD, USA. [email protected]

John A Carter Pfizer, Inc., Outcomes Research Medicines Development Group, Specialty Care Business Unit, Pfizer Global Development Headquarters, Groton, CT 06340, USA

Seema Haider Pfizer, Inc., Outcomes Research Medicines Development Group, Specialty Care Business Unit, Pfizer Global Development Headquarters, Groton, CT 06340, USA

Vinod K Rustgi Georgetown University Medical Center, Washington, DC, USA

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

Pfizer Inc. provided funding to Pharmerit North America LLC to conduct this research. S Haider is an employee of Pfizer Inc. X Gao, JM Stephens and JA Carter are employees of Pharmerit North America LLC. VK Rustgi has been a consultant to Merck and Vertex, has been on advisory boards for Merck, Vertex, Janssen, Bristol-Myers Squibb and Gilead, and has received research grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Vertex and Gilead. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C

Information for

Open access

Opportunities

Help and information

Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature